BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.17−1.37 (-1.72%)
Close on Nov 12, 2026Market cap $15.23BP/E –Yield –
BridgeBio Pharma total assets
Total assets on the balance sheet at the end of each period.
BridgeBio Pharma's total assets was $2.16B at Sep 30, 2026. For fiscal 2025 it was $936.03M, up 1.8% from the year before. The highest annual figure on record is $1.01B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $936.03M | +1.8% |
| FY2024 | Dec 31, 2024 | $919.34M | +68.3% |
| FY2023 | Dec 31, 2023 | $546.38M | -12.3% |
| FY2022 | Dec 31, 2022 | $623.04M | -38.5% |
| FY2021 | Dec 31, 2021 | $1.01B | +43.9% |
| FY2020 | Dec 31, 2020 | $703.59M | +11.4% |
| FY2019 | Dec 31, 2019 | $631.68M | +35.9% |
| FY2018 | Dec 31, 2018 | $464.94M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.16B | +116.6% |
| Q2 FY2026 | Jun 30, 2026 | $1.22B | +12.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.37B | +55.5% |
| Q4 FY2025 | Dec 31, 2025 | $936.03M | +1.8% |
| Q3 FY2025 | Sep 30, 2025 | $998.25M | +50.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.08B | +36.0% |
| Q1 FY2025 | Mar 31, 2025 | $881.64M | +3.8% |
| Q4 FY2024 | Dec 31, 2024 | $919.34M | +68.3% |
| Q3 FY2024 | Sep 30, 2024 | $664.98M | +1.5% |
| Q2 FY2024 | Jun 30, 2024 | $794.38M | +57.7% |
| Q1 FY2024 | Mar 31, 2024 | $849.33M | +35.7% |
| Q4 FY2023 | Dec 31, 2023 | $546.38M | -12.3% |
| Q3 FY2023 | Sep 30, 2023 | $655.01M | -10.1% |
| Q2 FY2023 | Jun 30, 2023 | $503.66M | -41.6% |
| Q1 FY2023 | Mar 31, 2023 | $625.68M | -23.1% |
| Q4 FY2022 | Dec 31, 2022 | $623.04M | -38.5% |
| Q3 FY2022 | Sep 30, 2022 | $728.74M | -6.8% |
| Q2 FY2022 | Jun 30, 2022 | $862.23M | -20.3% |
| Q1 FY2022 | Mar 31, 2022 | $813.15M | -25.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.01B | +43.9% |
| Q3 FY2021 | Sep 30, 2021 | $781.52M | -0.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.08B | +19.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.09B | +10.5% |
| Q4 FY2020 | Dec 31, 2020 | $703.59M | +11.4% |
| Q3 FY2020 | Sep 30, 2020 | $787.69M | +23.0% |
| Q2 FY2020 | Jun 30, 2020 | $905.23M | +94.7% |
| Q1 FY2020 | Mar 31, 2020 | $989.80M | – |
| Q4 FY2019 | Dec 31, 2019 | $631.68M | – |
| Q3 FY2019 | Sep 30, 2019 | $640.53M | – |
| Q4 FY2018 | Dec 31, 2018 | $464.94M | – |
See a number that looks wrong?